Harmony Biosciences Announces Leadership Change Amid Market Sell-Off
On Monday, Harmony Biosciences (HRMY) experienced a significant drop in its stock price after announcing that Peter Anastasiou will become CEO on January 1, 2027. The change is part of a planned succession replacing current CEO Jeffrey Dayno, who has been instrumental in the development and success of Wakix, Harmony's FDA-approved drug for sleep disorders. Despite reiterating its strategic priorities — including continued development of pitolisant (Wakix) and maintaining full-year revenue guidance between $1 billion to $1.04 billion — investors reacted negatively, causing a more than 5% decline in the stock price. The company emphasized that key commercial and pipeline milestones remain unchanged. While some analysts suggest there is little reason for concern given the continuity of strategy, market sentiment appears sensitive due to leadership transitions at successful companies.
Tickers: $HRMY